ImaginAb and [Yantai] DongCheng Pharmaceutical Group Sign Exclusive License Agreement to Commercialize CD8 ImmunoPET Agent in China to Serve Pharma and Healthcare Community

/in

Los Angeles, USA and Yantai, China – May 24th, 2022 – ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce the signing of an exclusive license with [Yantai] DongCheng Pharmaceutical Group to commercialize ImaginAb’s CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab […]

Read more

Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into an exclusive licensing agreement with Cooper Consumer Health  (“Cooper”), a leading European independent self-care organisation, for the rights to commercialise the […]

Read more

Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia

/in

Deal value includes upfront payment of US$100 million with F2G eligible for additional regulatory and commercial milestones of up to US$380 million, as well as double-digit royalties on net sales and share development costs Validation of Novo Holdings’ strategy to identify and invest in promising European biotech opportunities Novo Holdings A/S, a leading international life sciences […]

Read more

DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology

/in

Turku, Finland – 18 May 2022: DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Anticancer Bioscience Ltd., an innovative China-base and international company pioneers in synthetic lethal approaches to precision oncology, today announced a notable collaboration pertaining to the development of silica-based long-acting controlled release treatments in oncology. The collaboration joins […]

Read more

Sofinnova Partners and Apollo form strategic partnership in life sciences

/in

NEW YORK & PARIS (May 16, 2022) – Apollo (NYSE: APO) and Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced a long-term strategic and financial partnership. Under the agreement, Apollo will take a minority equity interest in Sofinnova and commit up to €1 billion of managed capital to […]

Read more
© Optimum Strategic Communications.